November 25, 2019, Sydney Nano Hub

Cardiovascular Precision Medicine Symposium

Presented by the University of Sydney Cardiovascular Initiative & the Australian Cardiovascular Alliance

Moving Towards Precision in Diagnosing, Preventing and Treating Cardiovascular Disease

We would like to acknowledge our sponsors:

Bioplatforms Australia, Broad Institute of MIT and Harvard, Australian Phenomics Network, Amgen, Sanofi and Sydney Health Partners

AGENDA10:00-10:30 Registration

10:30 Opening

10:30 Cardiovascular Disease Today – The Hon. Greg Hunt MP (by video)

10:37 The Current Climate for Cardiovascular Precision Medicine –Prof. Gemma Figtree, ACvA President

10:44 Welcome and Acknowledgement of Country – Prof. Duncan Ivison, DVCR University of Sydney

10:50 Plenary Session Chair – Dr Tony Penna

10:50 What is the “ultimate precision medicine” and what it would have meant for me? – a patient perspective – Mr Ian Hutchison

10:55 What new technology and approaches can do to improve the precision of early detection, prevention and treatment in the cardiovascular system – Prof. Patrick Ellinor, Broad Institute of MIT and Harvard

11:25-11:40 Morning Tea

11:40 Session 1: Platforms to catapult discovery of new mechanisms and markers for CVD

Chairs – Prof. Tony Keech and Dr David Abbott

1. Integrating clinical and molecular datasets at scale: challenges and solutions – Dr Anthony Philippakis (by video), Broad Institute of

MIT and Harvard2. Molecular phenotyping using state-of-art omics platforms – Prof. Peter

Meikle, Baker IDI3. Advanced Cardiovascular Imaging to enhance clinical phenotyping and

discovery – Prof. Stuart Grieve, Heart Research Institute

4. Polygenic risk scores in cardiovascular disease – Dr Gad Abraham, Baker IDI

5. Embedding new biomarkers in clinical trials and cohorts and evaluating related mechanisms – Prof. Alicia Jenkins, NHMRC Clinical Trials Centre

6. Embedding clinical trials and cohort studies into clinical practice, and optimising efficiency through linked data – Prof. Derek Chew, SAHMRI

13:10-13:50 Lunch

13:50 Session 2: What is the Clinical Gap – with panel discussion

Chairs – Prof. Patrick Ellinor and Ms Erica Kneipp

1. Atherosclerosis- detection of early disease, and the missing biology – A. Prof. Sanjay Patel, Interventional Cardiologist, RPAH

2. Cardiomyopathy and heart failure – Prof. Chris Semsarian, Centenary Institute

3. Atrial fibrillation – Prof. Diane Fatkin, Victor Chang CRI4. Genetic protection against cardiovascular disease: Lessons from the

resilient – Dr Paul Lacaze, Monash University 5. Extraction of functional information from large-scale genomic data –

Prof. Daniel Macarthur, Broad Institute of MIT and Harvard6. Demonstrating clinical benefit- how to use the emerging panel of

markers to improve individual patient care – Prof. Tony Keech, NHMRC Clinical Trials Centre

Panel Discussion - next steps and opportunities

15:25-15:40 Afternoon Tea

15:40 Session 3: Translation and CommercializationChairs – Ms Anne O’Neill and Prof. David Celermajer AO

1. Pharma Perspective – Dr Ricardo Dent, Clinical Research Medical Director, Amgen global HQ

2. Next generation cardiac biomarkers for the acute setting and primary prevention – Dr Agim Beshiri, Senior Medical Director, Global Medical and Scientific Affairs, Abbott

3. The role of the LHD in discovery and translation – Dr Kerry Chant PSM, Chief Health Officer, Dep Sec Population and Public Health, NSW Health

4. Imaging perspective – Dr Kieran O’Brien, Head of Collaborations & Research for Australia/New Zealand, Siemens Healthcare

16:40 Session 4: Rising Stars (5min/speaker, including questions)

Chair Associate Prof. Aaron Sverdlov

1. Evaluating the Prognostic Significance of Unexplained Left Ventricular Late Gadolinium Enhancement (LGE): A Cardiac Magnetic Resonance (CMR) Imaging Follow-Up Study – Paraskevi Morris, Discipline of Pathology, University of Sydney

2. Multivariate genome-wide association analysis of a cytokine network reveals variants with widespread immune, haematological and cardiometabolic pleiotropy – Dr Artika Nath, Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute

3. Novel assay assesses heightened procoagulant platelet response and its potential as a biomarker to inform on individual thrombotic risk – Dr Christine Lee, ANZAC Research Institute, Sydney

Finalists chosen from poster abstracts submitted give 5-minute presentations. Professor’s Alicia Jenkins, Peter Meikle, Associate Professor Aaron Sverdlovto judge Young Investigators Award for Outstanding Science Communication

15:40 Networking drinks & Poster SessionAward for best poster announced at 5.45pm

Professor Duncan IvisonDuncan is currently Deputy Vice Chancellor (Research) and Professor of Political Philosophy at the University of Sydney. Prior to this he was Dean of the Faculty of Arts and Social Sciences (2010-2015) and Head of the School of Philosophical and Historical Inquiry (2007-2009). Duncan has also held appointments at the University of Toronto, the University of York (UK) and was a Postdoctoral Fellow at the Research School of Social Sciences at the ANU. He did his BA at McGill University in Montreal, where he grew up, and his MSc and PhD at the London School of Economics and Political Science. He is currently Chair of the University of Sydney Confucius Institute Board; Chair of the Group of Eight DVCR Committee; Chair of the NSW DVCR/PVC Committee; member of the Australian Research Council’s Advisory Council; and board member of the venture fund Uniseed. duncan.ivison@sydney.edu.au

Professor Gemma FigtreeGemma Figtree is a Professor in Medicine at the University of Sydney. She is committed to the promotion and advocacy of cardiovascular research and improving the care for heart attack patients. Combining her knowledge and experience as an interventional cardiologist with her knowledge of molecular and cellular biology her research focusses on developing methods of identifying those at highest risk of adverse outcome and discovering novel therapies to prevent and treat events. Gemma has been awarded a National Health and Medical Research Council (NHMRC) Excellence Award for Top Ranked Practitioner Fellow (Australia), commencing in 2018. In 2019 she received the Ministerial Award for Cardiovascular Research Excellence.She is Chair of the University of Sydney’s multi-disciplinary Cardiovascular Initiative, co-leads the Cardiovascular Theme for Sydney Health Partners, and is President of the Australian Cardiovascular Alliance (ACvA). In her role as ACvA President Gemma led the proposal to secure Federal funding for the Mission for Cardiovascular Health.gemma.figtree@sydney.edu.au

Mr Ian Hutchinson Ian regarded himself as a fit and healthy 55-year-old father. He walked the dog each morning and went on bike rides or to the gym most days. He’d never smoked and rarely drank alcohol. In September 2018, while bike riding with his mate Donald MacKee, he had a sudden cardiac arrest. Thanks to some quick thinking by Donald and some good Samaritan CPR bystanders, 000 was called, CPR commenced, and Ian became one of the lucky 9% to survive an out-of-hospital sudden cardiac arrest.

Dr Antonio PennaTony is a paediatrician and medical administrator. He specialised in paediatric pharmacology and undertook clinical research for over a decade before he moved into administration. Tony was a medical administrator at Westmead Hospital and Royal North Shore Hospital before taking on the position of Chief Executive of the Children's Hospital at Westmead for 5 years. In August 2013 he was appointed as Director of the Office for Health and Medical Research in the NSW Ministry of Health. ‘My leadership style is very much about active engagement with the people that make up the health and medical research community, developing relationships that will assist me in understanding better the challenges and opportunities that confront them so that I can best serve them in the privileged leadership role that I have been appointed to.’ Antonio.Penna@health.nsw.gov.au

Professor Patrick EllinorPatrick attended Stanford University for medical and graduate school. After completing doctoral work in the laboratory of Dr. Richard Tsien on the structure and function of calcium channels, he completed his residency at Brigham and Women’s Hospital and his cardiology and cardiac electrophysiology fellowship at MGH. He joined the staff of MGH in 2001, and served as the Medical Director of the Cardiac Step-Down Unit for thirteen years. He became the Director of the Cardiac Arrhythmia Service in 2016, and he is a Professor at Harvard Medical School. At the Broad Institute of MIT and Harvard, he is an Institute Member and the Director of the Cardiovascular Research Initiative. pellinor@broadinstitute.org

Professor Anthony KeechTony is a cardiologist, epidemiologist and internationally renowned clinical trials researcher. As Deputy Director of the NHMRC Clinical Trials Centre (CTC) he co-leads a team of researchers involved in the rigorous conduct of large investigator-initiated randomised controlled trials and epidemiological studies, which address questions important to human health. Recognised for his work in cardiovascular disease (CVD) and diabetes, he has led some of the largest CVD trials in the world. His research has had a major impact on clinical practice and outcomes, particularly in the treatment of acute myocardial infarction, dyslipidaemia, CVD, and the prevention and treatment of chronic heart disease, diabetes and its complications. He has helped to identify the value of aspirin and clot-busting drugs in heart attack. His research findings have altered clinical guidelines and influenced policy and subsidy decisions. As co-leader of the Heart Protection Study and the Cholesterol Treatment Trialists’ Collaboration and a lead investigator of the LIPID study and the FOURIER trial, his research has demonstrated the benefit and safety of long-term cholesterol lowering therapy in at-risk patients. Tony also oversees collaborative basic research, having established a high-throughput biomarker laboratory led by Professor Alicia Jenkins with the aim of identifying biomarkers of diagnosis or response to treatment for diabetes and vascular diseases. anthony.keech@sydney.edu.au

Dr David AbbottDavid is the Principal Research Scientist in the Health and Medical Research Office (HMRO), Commonwealth Department of Health. HMRO is responsible for managing the Medical Research Future Fund (MRFF). David has held this position for eighteen months. Prior to this he was employed by National Health and Medical Research Council (NHMRC) for over ten years; most recently as adviser to the CEO, but he also worked on NHMRC funding schemes (peer review) and managed the development of a number of key NHMRC evidence statements and guidelines. In 2016, David was seconded to the Department of Health for six months to work on the National Health Genomics Policy Framework, which was released in November 2017. David.Abbott@health.gov.au

Dr Anthony PhilippakisAnthony is the Chief Data Officer of the Broad Institute of MIT and Harvard, where he is also an institute scientist. He is committed to bridging the gap between data sciences and medicine. He is a cardiologist at Brigham and Women’s Hospital, where his primary focus is caring for patients with rare genetic cardiovascular diseases. At the Broad Institute he directs the Data Sciences Platform, an organization of over 100 software engineers and computational biologists that develops software for analyzing genomic and clinical data. In addition to his roles at the Broad Institute and Brigham and Women’s Hospital, Philippakis is a Venture Partner at GV, focusing on machine learning, distributed computing, and genomics. Anthony received his M.D. from Harvard Medical School and completed a Ph.D. in biophysics at Harvard. As an undergraduate, he studied mathematics at Yale University, and later completed the Part III (equivalent to M.Phil) in mathematics at Cambridge University. aphilipp@broadinstitute.org

Professor Peter MeikleProfessor Peter Meikle is the Head of the Systems Biology Domain and the Metabolomics Laboratory at the Baker Heart and Diabetes Institute. He is co-Director of the ACvA Precision Medicine Flagship and Editor in Chief of Metabolites, the official Journal of the International Metabolomics Society. His research has a focus on the dysregulation of lipid metabolism associated with obesity, diabetes and cardiovascular disease and its relationship to the pathogenesis of these disease states. This work is leading to new approaches to early diagnosis and risk assessment, and to the development of new lipid modulating therapies for chronic disease. Peter.Meikle@baker.edu.au

Professor Stuart GrieveStuart is a clinician/scientist with a career focus on applying non-invasive imaging in healthcare and achieving fundamental advances in basic imaging science such as new imaging or image processing technologies. He is the Parker Hughes Professor of Radiology at the University of Sydney (USYD) and also a radiologist at Royal Prince Alfred Hospital (RPAH). His team at the Charles Perkins Centre pursues a research program that extends from basic imaging science, post-processing, basic physiology of the cardiovascular system and brain to clinical translational studies that aim to directly alter practice. The major focus of his research is the quantitative analysis imaging data, especially direct measures of neurological, blood flow and myocardial function using MRI. There is a large bias in his work toward imaging methods that are amenable to computational methods, as well as to the use of computational simulations that are informed by real data. stuart.grieve@sydney.edu.au

Dr Gad AbrahamGad received the BAppSci(Hons) in computer science from RMIT University in 2005, and a PhD at the University of Melbourne in 2012. He then began a postdoctoral fellowship at the Department of Pathology at the University of Melbourne (2012–2015) and later became a group leader and Core Member at the Centre for Systems Genomics, School of BioSciences, University of Melbourne (2015–2017). In mid 2017, he joined the Baker Institute as a Group Leader in the Systems Genomics Laboratory. His main research interest has been the development of genomic (polygenic) risk scores for complex human disease, including coeliac disease and more recently coronary heart disease. Such scores have the potential to stratify individuals by disease risk early in life, better tailoring treatment or lifestyle modifications to individuals, years or decades before disease manifests. He also has an interest in development of computational tools and methods for practical analysis of large genomic and multi-omic datasets. Gad.Abraham@baker.edu.au

Professor Alicia JenkinsAlicia is a clinician researcher endocrinologist and Professor, Diabetes and Vascular Medicine at the NHMRC Clinical Trials Centre, Uni of Sydney. She is co-Director of the ACvA Precision Medicine Flagship. Alicia has a Biomarker Laboratory with expertise in clinical, biochemical and molecular markers of relevance to diabetes and vascular disease. She leads clinical trials in diabetes complications. Alicia holds a NHMRC Practitioner Fellowship and has over 370 publications. alicia.jenkins@ctc.usyd.edu.au

Professor Derek ChewDerek is a clinical and interventional cardiologist as well as a clinical trialist and outcomes researcher in cardiovascular medicine. He has completed a Masters of Public Health at the Harvard School of Public Health, with formal training in epidemiology, trial design, biostatistics, clinical trials and cost-effectiveness analysis. His PhD thesis explored the factors for improving heart attack care in Australia. Derek’s current appointment is Professor of Cardiology Flinders University and is the Network Director of Cardiology for the Southern Adelaide Health Local Health Network. He leads the Heart and Vascular program of the SAHMRI and co-leads the Lifelong Health Theme. He has national and international roles in chest pain/ACS evidence generation, assimilation and translation. In clinical guideline development he has led the Heart Foundation/CSANZ ACS Guidelines writing group 2016 and served on the European Society of Cardiology Guidelines for the management of ACS Writing committee 2015. In addition, he chairs the Cardiovascular Disease Expert Advisory Group, the primary CV disease monitoring body of the AIHW; while providing expert advice to the Australian Commission for Quality and Safety in Health care). He also Chairs the Quality Standards Committee of the Cardiac Society of Australia and New Zealand, and the Clinical Committee of the Heart Foundation. He has authored over 280 manuscripts and book chapters. derek.chew@flinders.edu.au

Ms Erica KneippErica’s experience spans all levels of government, the private and not-for-profit health sectors in Australia and she is known for her passion for evidence basedpolicy development and research praxis. She has recently joined the Australian National University, after a decade in Commonwealth Health supporting a number of national portfolios and Ministers. She was instrumental in establishing the Medical Research Future Fund and Biomedical Translation Fund and worked with states to position Australia as a preferred destination for clinical trials. erica.kneipp@health.gov.au

Professor Sanjay PatelSanjay is a Staff Interventional Cardiologist and Director of the Cardiac Catheterisation Laboratory, Royal Prince Alfred Hospital; Group Leader at the Heart Research Institute, Sydney and Clinical Associate Professor at the Sydney Medical School. He was awarded his MBBS (Hons 1) from The University of Sydney in 2000; completed his advanced cardiology training at Royal Prince Alfred Hospital in 2006; his doctoral studies in 2009, supported by a NHF postgraduate research scholarship; and his postdoctoral studies at Stanford University, while simultaneously training in interventional cardiology at Stanford University Medical Centre (2009–2010), supported by an NHMRC CJ Martin Overseas Fellowship Grant. Sanjay.Patel@hri.org.au

Professor Chris SemsarianChris is a Professor of Medicine at University of Sydney, Program Head, Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, and Cardiologist and Director, Genetic Heart Disease & Hypertrophic Cardiomyopathy Clinics, Royal Prince Alfred Hospital. Chris has established a research program at the interface of basic science, clinical research and public health, with the goal to prevent complications of genetic heart diseases in our community and prevent sudden cardiac death, particularly amongst children and young adults. He is the co-lead of the Cardiovascular Genetic Diseases Flagship of Australian Genomics. He has published over 250 peer-reviewed scientific publications, in the highest-ranking cardiovascular and general medical journals. Chris has also been the primary supervisor of over 30 PhD, honours, and medical honours students since 2003, and is an active member of the mentoring program at the University of Sydney, particularly in supporting gender equity. He has led major community programs in the area of prevention of sudden death, including having defibrillators in all public places, and programs teaching CPR to community members. Prof Semsarianwas awarded a Member in the General Division of the Order of Australia (AM) on January 26, 2017 for significant service to medicine in the field of cardiology as a clinician, administrator and educator, and to the community. christopher.semsarian@sydney.edu.au

Professor Diane FatkinDiane is head of the Sr Bernice Research Program in Inherited Heart Diseases, Molecular Cardiology Division, Victor Chang Cardiac Research Institute, with appointments as Honorary Medical Officer in the Cardiology Department, St Vincent’s Hospital, and Professor (conjoint) in the Faculty of Medicine, University of New South Wales. Her research is focussed on the clinical management and molecular genetics of inherited cardiomyopathies in particular, familial dilated cardiomyopathy and familial atrial fibrillation. d.fatkin@victorchang.edu.au

Dr Paul Lacaze Paul is the inaugural Head of Public Health Genomics at Monash University and 2019 Heart Foundation Future Leader Fellow. He conducts research into the role of genetic data in public and population health, through large-scale cohort studies, biobanks, clinical trials and registries. He leads genomics for the ASPREE and STAREE studies, Australia’s largest clinical trials and studies of healthy ageing (>15,000 Australians). His research focuses on the concept of genetic protection or ‘resilience’ against disease in the healthy elderly, and the role of protective variants. He also conducts research into the ethical, legal and social issues associated with use of genomic information in society. He founded the Australian Non-Genetic Discrimination Working Group, a national body advocating for regulatory change around the use of genetic test results in life insurance. He has a PhD from the University of Edinburgh. paul.lacaze@monash.edu

Associate Professor Daniel MacArthurDaniel is co-director of the Medical and Population Genetics Program at the Broad Institute of MIT and Harvard Medical School. Daniel completed his PhD in Sydney, then served as a postdoctoral fellow at the Wellcome Trust Sanger Institute UK, and now co-leads the Broad’s Center for Mendelian Genomics and is group leader in the Analytic and Translational Genetics Unit at Massachusetts General Hospital in Boston, USA. His work revolves around the use of large-scale genomic data to interpret genetic variants, particularly in the context of rare, severe genetic diseases. MacArthur’s team has assembled the largest collection of sequences of the protein-coding region (exome) of the human genome, creating the Genome Aggregation Database (gnomAD), a reference database of DNA sequence data from >140,000 individuals. At the Broad Institute's Center for Mendelian Genomics, MacArthur uses DNA and RNA sequencing technologies to investigate the genetic basis of rare diseases in thousands of families every year, returning genetic diagnoses to over 2,000 families to date, and identifying over 150 new candidate genes associated with a wide variety of diseases. danmac@broadinstitute.org

Anne O’NeillAnne is Director, Enterprise and International Partnerships, NSW Office for Health and Medical Research, Ministry of Health. She has over 20 years’ experience in the health, medical research and policy sectors. She is responsible for leading the development and implementation of major policies and programs to enhance medical research capacity in NSW and raise the profile of NSW research and development nationally and internationally. She has particular responsibility for the NSW Medical Device Fund and NSW Medical Device Commercialisation Training Program – both have been critical to accelerating the development of NSW IP and the next generation of innovators and entrepreneurs in NSW. Anne is also responsible for developing international partnerships in medical research and commercialisation. Anne.ONeill2@health.nsw.gov.au

Professor David CelermajerDavid Celermajer is the Scandrett Professor of Cardiology at the University of Sydney and Royal Prince Alfred Hospital. He has published extensively on many aspects of Cardiovascular disease, particularly early detection techniques. His H-index is over 100 and career citations over 45,000.His main research interests are in early detection and thereby prevention of heart and vascular diseases, thereby “personalising” risk by careful phenotyping and then selecting the right treatments for the right patients. David.Celermajer@health.nsw.gov.au

Dr Ricardo DentRicardo is a clinical research medical director for the Cardiometabolic Therapeutic Area at the corporate headquarters in Thousand Oaks, California. He completed his medical training in Internal Medicine and Pediatrics at the Louisiana State University Health Sciences Center in Shreveport, Louisiana in 2005. From 2005 to 2008 Ricardo worked as a clinical reviewer for the U.S. Food & Drug Administration in Silver Spring, Maryland. In 2008 Ricardo joined Amgen to work as a clinical scientist on the development program of Prolia and Evenity for osteoporosis and fracture healing. In 2012 Ricardo began working on the Repatha clinical research program and was responsible for the statin intolerance, device home use, and open-label extension studies. rdent@amgen.com

Dr Agim BeshiriAgim is Senior Medical Director of Medical and Scientific Affairs for Abbott Diagnostics. Prior to his work at Abbott, his medical background encompassed internal medicine and laboratory medicine. His clinical experience includes the Brooke Army Medical Center in Texas, the 452nd Combat Support Hospital in Wisconsin and Aurora/Advocate Clinical Laboratories in Wisconsin and Illinois as well as the Ministry of Health in Macedonia. Agim completed his studies and training at the University of Wisconsin, UNIBE School of Medicine and the Academy of Health Sciences (U.S. Army). Previously, he served as the American Association of Clinical Chemistry Industry Division Secretary. He is a member of several organizations, including the American College of Cardiology, American Heart Association, European Society of Cardiology, International Council for Standardization in Hematology, International Society for Laboratory Hematology, European Hematology Association, American Society of Hematology, and American Society of Clinical Oncology. Agim has also served on guideline subcommittees for the Clinical and Laboratory Standards Institute. agim.beshiri@abbott.com

Dr Kerry Chant PSMKerry is Deputy Secretary, Population and Public Health and Chief Health Officer, NSW Health. She leads the Population and Public Health Division which has accountabilities for a broad portfolio of issues, including tobacco control, reduction of risk drinking and obesity, the promotion of physical activity, end of life care and organ donation. She has a particular interest in the response to HIV, hepatitis C and hepatitis B and Aboriginal Health. kerry.chant@health.nsw.gov.au

Dr Kieran O’BrienKieran is a Siemens Healthcare Adjunct Research Fellow at the Centre for Advanced Imaging. He completed his Bachelor of Biomedical Engineering (Honours, 2005) and PhD in Bioengineering from the University of Auckland in 2009. After being awarded his PhD in Cardiac MRI, Kieran worked in Postdoctoral positions at the University of Auckland and the University of Geneva Centre d'Imagerie BioMédicale before joining Siemens as a Senior Scientist in 2013. His research interests include improving RF pulses at high field (≥3T) to overcome imaging inhomogeneity and B1 limitations for Neuro, MSK and Cardiac applications; bi-exponential diffusion imaging; and, phase imaging for quantitative susceptibility mapping and measuring flow. In 2019 he took on the Collaboration and Research responsibilities for ANZ, overseeing a team of 5 scientists across the Siemens business. kieran.obrien@siemens-healthineers.com

Associate Professor Aaron SverdlovAaron is a heart failure cardiologist and a clinician scientist. He is an Associate Professor and Director of Heart Failure at the University of Newcastle and Clinical Lead for Heart Failure Services for Hunter New England LHD. He is a Co-director of Cardiometabolic and Vascular Research Group and Clinical lead and a Co-director of the bench-to-bedside “Cancer and the Heart” research and clinical program at the University of Newcastle/Hunter New England LHDa Co-director of Cardiometabolic and Vascular Research Group at the University of Newcastle. Aaron completed his medical degree, cardiology training and PhD in Adelaide, and then undertook Postdoctoral Fellowship in Heart Failure at Boston University. He is a past NHMRC CJ Martin Fellow, AHA postdoctoral Fellow and is a current Heart Foundation of Australia Future Leader Fellow. His clinical and research interests encompass a broad spectrum of topics related to heart failure, from fundamental mechanistic research all the way to models of care and service delivery, and cardio-oncology (cardiovascular complications of cancer therapies). Aaron is an associate editor of Heart Lung and Circulation and an editorial board member of Hypertension and Reactive Oxygen Species. aaron.Sverdlov@newcastle.edu.au

We acknowledge the tradition of custodianship and law of the Country on which the University of Sydney campuses stand. We pay our respects

to those who have cared and continue to care for Country.

CRICOS 00026A

For more information:Cardiovascular Initiative W https://sydney.edu.au/research/centres/cardiovascular-initiative.htmlE vicki.snelson@sydney.edu.au